Bisphosphonates in the treatment of skeletal metastases
- 1 October 2004
- journal article
- review article
- Published by Elsevier in Seminars in Oncology
- Vol. 31, 59-63
- https://doi.org/10.1053/j.seminoncol.2004.07.024
Abstract
No abstract availableKeywords
This publication has 39 references indexed in Scilit:
- Role of bisphosphonates in prostate cancer bone metastasesSeminars in Oncology, 2003
- Zoledronic acid for the treatment of bone metastases in patients with breast cancer and other solid tumorsSeminars in Oncology, 2003
- Bone metastases: Approaches to managementSeminars in Oncology, 2001
- Metastatic bone disease: clinical features, pathophysiology and treatment strategiesCancer Treatment Reviews, 2001
- Management of Bone MetastasesThe Oncologist, 2000
- Predictors of skeletal complications in patients with metastatic breast carcinomaCancer, 2000
- Treatment of Metastatic Bone Disease in Breast Cancer: BisphosphonatesClinical Breast Cancer, 2000
- Pamidronate prevents skeletal complications and is effective palliative treatment in women with breast carcinoma and osteolytic bone metastasesCancer, 2000
- Pamidronate Reduces Skeletal Morbidity in Women With Advanced Breast Cancer and Lytic Bone Lesions: A Randomized, Placebo-Controlled TrialJournal of Clinical Oncology, 1999
- The role of bisphosphonates in the treatment of painful metastatic bone disease: a review of phase III trialsPain, 1998